Group 1 - The hair medical concept sector declined by 0.70%, ranking among the top declines in concept sectors, with notable declines in companies such as International Medicine, Kanghui Co., and Langzi Co. [1] - Among the hair medical concept stocks, five companies saw price increases, with *ST Meigu rising by 2.68%, *ST Jinbi by 2.12%, and Baicheng Pharmaceutical by 1.31% [1][3] - The main capital outflow from the hair medical concept sector today was 336 million yuan, with 18 stocks experiencing net outflows, and 10 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net capital outflows were led by Kids Wang with a net outflow of 96.59 million yuan, followed by Aimeike with 65.02 million yuan, International Medicine with 31.64 million yuan, and Shuiyang Co. with 30.71 million yuan [2] - The stocks with the highest net capital inflows included Kanghui Co. with 3.44 million yuan, *ST Jinbi with 2.01 million yuan, and Xiaofang Pharmaceutical with 1.34 million yuan [2] - The hair medical concept sector had a notable trading volume, with Kids Wang showing a turnover rate of 9.49% and Aimeike at 1.43% [2][3]

西安国际医学投资股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示 1.本次股东会会议召开期间没有增加、否决或变更提案。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-058 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1.现场会议召开时间：2025年12月19日（星期五）下午2:30 网络投票时间为：2025年12月19日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年12月19日的交易时间，即09:15一09:25，09:30一11:30和13:00一15:00；通过深圳证券交易所互联 网系统投票的具体时间为：2025年12月19日09:15一15:00期间任意时间。 2.现场会议召开地点：西安市高新区西太路737号西安国际医学中心医院北院区保障楼5层会议室 3.召开方式：本次股东会采取现场投票与网络投票相结合的方式 4.召集人：西安国际医学投资股份有限公司董事会 5.主持人：史今 ...

Core Viewpoint - International Medicine (000516.SZ) plans to raise up to 1.008 billion yuan through a private placement, focusing on three main areas: smart healthcare projects, proton therapy center phase II, and working capital supplementation [2][4] Group 1: Fundraising and Investment Focus - The fundraising will allocate 638 million yuan to smart healthcare projects, nearly 100 million yuan to the proton therapy center phase II, and 270 million yuan for working capital [2] - The smart healthcare project aims to utilize idle assets to "activate stock assets," responding to both policy demands and the need for asset revitalization [2][5] - The company intends to use 270 million yuan from the fundraising to meet operational funding needs and optimize its capital structure [2][5] Group 2: Financial Challenges - As of September 30, 2025, the company's debt-to-asset ratio reached 68.80%, significantly higher than the industry average, with a sharp decline in cash reserves from 1.52 billion yuan at the end of 2021 to 331 million yuan [4][7] - The company has substantial short-term borrowings of 995 million yuan and non-current liabilities due within a year totaling 905 million yuan, leading to a total of nearly 1.9 billion yuan in rigid debt due within a year [4] - The company has faced significant losses over the past four years, with cumulative losses reaching 2.621 billion yuan [7] Group 3: Market Opportunities and Strategic Adjustments - The company views the fundraising as a strategic adjustment to address market changes, financial pressures, and idle assets [3] - The smart healthcare project and proton therapy center phase II are seen as key initiatives to capitalize on the "silver economy" and high-end medical development opportunities [4][6] - The proton therapy center phase II aims to fill a market gap in the northwest region, where no proton therapy centers are currently operational [6] Group 4: Operational Efficiency and Cost Management - The company is attempting to improve operational efficiency through clinical pathway management and cost structure optimization [8][9] - As of the third quarter of 2025, the company reported a management expense ratio of 10.99%, a decrease from previous periods, indicating initial success in cost control [8] - The company plans to continue enhancing service quality and patient experience while exploring various specialized medical fields to build competitive advantages [9]

证券日报网讯 12月19日晚间，国际医学（000516）发布公告称，公司2025年第二次临时股东会审议通 过《关于公司符合向特定对象发行股票条件的议案》《关于公司向特定对象发行股票方案的议案》《关 于公司2025年度向特定对象发行股票预案的议案》等多项议案。 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-058 西安国际医学投资股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1.本次股东会会议召开期间没有增加、否决或变更提案。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1.现场会议召开时间：2025 年 12 月 19 日（星期五）下午 2:30 网络投票时间为：2025 年 12 月 19 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 12 月 19 日的交易时间，即 09:15—09:25，09:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网系统投票的具体时间为：2025 年 12 月 19 日 09:15—15:00 期间任意时间。 2.现场会议召开地点：西安市高新区西太路 737 号西安国际医学中心 医院北院区保障楼 5 层会议室 3.召开方式：本次股东会采取现场投票与网络投票相结合的方式 4.召集人：西安国际医学投资股份有限公司董事会 5. ...

北 京 市 康 达 （ 西 安 ） 律 师 事 务 所 BEIJING KANGDA (XI'AN) LAW FIRM 陕西省西安市太白南路 139 号荣禾·云图中心 7 层、15、24 层 7&15F, Ronghe Cloud Centre, No.139, South Taibai Road, Xi'an, Shaanxi Province, P.R.C 邮编/Zip Code:710065 电话/Tel:029-88360128 传真/Fax:029-88360129 北京市康达（西安）律师事务所 关于西安国际医学投资股份有限公司 2025 年第二次临时股东会的 法 律 意 见 书 致: 西安国际医学投资股份有限公司 北京市康达（西安）律师事务所接受西安国际医学投资股份有限公司（以下 简称"公司"）的委托，指派田慧律师、吕岩律师（以下简称"本所律师"）出 席公司 2025 年第二次临时股东会（以下简称"本次股东会"），并出具法律意 见书。 本所律师声明事项： 1.在本法律意见书中，本所律师仅就本次股东会的召集与召开程序、召集人 和出席会议人员的资格、会议的表决程序以及表决结果进行审查和见证后发表法 律 ...

Core Viewpoint - The company has confirmed that its non-public stock issuance aligns with its development strategy and has received necessary approvals from the board, shareholders, and regulatory authorities [2] Group 1 - The non-public stock issuance is intended to support the company's business development and enhance its operational capabilities [2] - The fundraising through non-public issuance is seen as beneficial for the long-term development of the company and the interests of all shareholders [2]

证券日报网讯 12月18日，国际医学在互动平台回答投资者提问时表示，大股东资信状况良好，具备较 强的资金偿还能力，不存在流动性风险，质押风险可控。 （文章来源：证券日报） ...

Core Viewpoint - The company is poised to leverage government policies supporting the development of social healthcare services, aiming to enhance medical service supply and optimize resource allocation in the healthcare sector [1] Group 1: Government Policies and Industry Context - The ongoing deepening of China's healthcare reform has led to a series of policy recommendations from central and local governments that encourage the development of social healthcare [1] - These policies are designed to increase the supply of medical services and ensure a rational allocation of healthcare resources [1] Group 2: Company Strategy and Operations - The company has over 20 years of experience in the healthcare industry, focusing on hospital construction, operation, and management [1] - It has developed a comprehensive lifecycle healthcare service platform, which is expected to enhance the utilization rate of hospital beds as the overall strength of hospitals improves and surrounding areas mature [1] - The company operates the Xi'an International Center Hospital, which has significant investment and currently has some vacant beds [1] Group 3: Future Growth Opportunities - The company plans to respond actively to national policies by seizing opportunities in the "silver economy," converting vacant beds into wellness beds to revitalize these assets [1] - This transformation of existing assets into high-value-added wellness services is expected to lay a solid foundation for future performance growth [1]

Group 1 - The high-pressure oxygen chamber concept increased by 2.20%, ranking fourth among concept sectors, with eight stocks rising, including Jinling Pharmaceutical, BeiYikang, and Innovation Medical, which rose by 6.35%, 5.73%, and 3.79% respectively [1] - The main capital inflow for the high-pressure oxygen chamber concept was 0.29 billion yuan, with five stocks receiving net inflows, led by Innovation Medical with a net inflow of 52.09 million yuan [2][3] - The net inflow ratios for International Medical, Innovation Medical, and Jinling Pharmaceutical were 9.48%, 5.21%, and 3.12% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, International Medical, and Jinling Pharmaceutical, while the top losers were Samsung Medical and Hangyang Co., which fell by 3.20% and 1.14% respectively [1][4] - The trading volume for Innovation Medical was 11.31%, indicating a high turnover rate, while other stocks like International Medical and Jinling Pharmaceutical had lower turnover rates of 1.77% and 4.54% respectively [3]